

Servaas Michielssens is the Head of Healthcare at Candriam since 2024. Previously, he was Senior Fund Manager and Biotechnology Analyst with Candriam from 2016 to 2022.
His other financial experience includes two years in private equity (from 2022), and two years as a risk analyst at Axa. Servaas began his career as a Doctoral Researcher at Katholieke Universiteit Leuven in 2007 and joined Max Planck Institute in Germany as a researcher in 2012.
Servaas holds a Master in Science and a Ph.D. in Chemistry (Katholieke Universiteit Leuven). He has been a CFA Charterholder since 2018.
Discover the latest articles by Servaas Michielssens

Servaas Michielssens, Linden Thomson, Equities
In 2000, Candriam took an audacious gamble : to invest in biotechnology, a field that was still little-followed by analysts at the time.

ESG, SRI, Healthcare, Servaas Michielssens, Linden Thomson
Time to Re-engage with Healthcare?
Healthcare share prices tend to reflect some trepidation leading up to and shortly after the US presidential elections, yet for the last five elections the sector outperformed in the 12 months following the election.

Servaas Michielssens, Healthcare
Healthcare and Biotechnology Market Update Following RFK Jr's Nomination
The healthcare and biotechnology sectors have experienced a downturn following the unexpected nomination of Robert F. Kennedy Jr. as Secretary of the Department of Health and Human Services (HHS).